Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 734 results for diabet*

  1. Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)

    Evidence-based recommendations on continuous subcutaneous insulin infusion (insulin pump therapy) for treating type 1 diabetes in adults and children.

  2. Tirzepatide for treating type 2 diabetes (TA924)

    Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.

  3. Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)

    Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes in adults.

  4. Dulaglutide for treating type 2 diabetes [ID1451]

    Awaiting development Reference number: GID-TA10439 Expected publication date: TBC

  5. Sotagliflozin for treating type 2 diabetes [ID1657]

    Awaiting development Reference number: GID-TA10665 Expected publication date: TBC

  6. Semaglutide for treating type 2 diabetes [ID1450]

    Awaiting development Reference number: GID-TA10438 Expected publication date: TBC

  7. Dulaglutide for treating type 2 diabetes in children and young people [TSID10660]

    Topic prioritisation

  8. Semaglutide for treating type 2 diabetes and associated peripheral arterial disease [TSID11791]

    Topic prioritisation

  9. Basal insulin icodec–semaglutide for treating type 2 diabetes inadequately controlled with daily basal insulin [TSID11940]

    Topic prioritisation

  10. Diabetes in pregnancy: management from preconception to the postnatal period - Managing type 1 diabetes (T1D) using hybrid closed loops (update)

    In development Reference number: GID-NG10450 Expected publication date: TBC

  11. Type 2 diabetes in adults: management (medicines update)

    In development Reference number: GID-NG10336 Expected publication date:  18 February 2026

  12. Semaglutide for treating type 2 diabetes in people 10 to 17 years [TSID12249]

    Topic prioritisation

  13. Orforglipron for treating type 2 diabetes [TSID12130]

    Topic prioritisation

  14. Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]

    In development Reference number: GID-TA10981 Expected publication date:  08 April 2026

  15. Insulin efsitora alfa for treating type 2 diabetes ID6499

    In development Reference number: GID-TA11644 Expected publication date:  22 October 2026